



PARTICIPANT STATISTICS

FIRST QUADRIMESTER 2011

LYME DISEASE

Lyme Disease Screen

| Method |
|----------------------------|
| bioMerieux Vidas IgG & IgM |
| GenBio ImmunoDOT EIA |
| Immunitics |
| Inverness ELISA Ig-unsp |
| Inverness FIAX IgG/IgM |
| DiaSorin LIAISON |
| Total Population |
| Flagging |

Specimen 1

| Neg | Pos |
|----------|-----------|
| | 10 |
| | 2 |
| | 2 |
| | 3 |
| | 2 |
| | 1 |
| 0 | 20 |
| ***** | |

Specimen 2

| Neg | Pos |
|-----------|----------|
| 10 | |
| 2 | |
| 2 | |
| 3 | |
| 2 | |
| 1 | |
| 20 | 0 |
| | ***** |

| No. of Labs |
|-------------|
| 10 |
| 2 |
| 2 |
| 3 |
| 2 |
| 1 |
| 20 |
| |

Lyme Disease Immunoblot

| Method |
|-------------------------|
| MarDx MARBLOT IgG |
| Total Population |
| Flagging |

Specimen 1

| Pos | Neg, TNP |
|----------|----------|
| 1 | |
| 1 | 2 |
| | |

Specimen 2

| Neg | Neg, TNP |
|-----|----------|
| | 1 |
| | 3 |
| | |

| No. of Labs |
|-------------|
| 1 |
| 3 |
| |

Due to a lack of participant consensus, specimen 1 was not evaluated this event.

Correct responses are defined as those reflecting agreement among 80% or more of all participants or referees. Unacceptable responses are indicated by "*****" on the Flagging line of each specimen.